Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

Published:2023-08 Issue:8 Volume:23 Page:956-964
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Jenkin Daniel,Wright Daniel,Folegatti Pedro M,Platt Abigail,Poulton Ian,Lawrie Alison,Tran Nguyen,Boyd Amy,Turner Cheryl,Gitonga John N,Karanja Henry K,Mugo Daisy,Ewer Katie J,Bowden Thomas A,Gilbert Sarah C,Charleston Bryan,Kaleebu Pontiano,Hill Adrian V S,Warimwe George M

Funder

Wellcome Trust

United Kingdom Department of Health and Social Care

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference29 articles.

1. Over 100 years of Rift Valley fever: a patchwork of data on pathogen spread and spillover;Bron;Pathogens,2021

2. Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle and man from east Africa;Daubney;J Pathol Bacteriol,1931

3. Clinical manifestations of Rift Valley fever in humans: systematic review and meta-analysis;Anywaine;PLoS Negl Trop Dis,2022

4. Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study;Baudin;Lancet Glob Health,2016

5. Rift Valley fever vaccines: current and future needs;Dungu;Curr Opin Virol,2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal–fetal placental interface;Journal of Virology;2024-08-20

2. Rift Valley Fever;Veterinary Clinics of North America: Food Animal Practice;2024-07

3. A promising boost for the Rift Valley fever vaccine pipeline;The Lancet Infectious Diseases;2024-07

4. Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial;The Lancet Infectious Diseases;2024-07

5. Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine;npj Vaccines;2024-06-26